Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.


TSX:DHT.UN - Post by User

User Avatar Image
(64)
•••
  • SONOFFERGUSX
Comment by SONOFFERGUSon Sep 09, 2024 4:49pm
88 Views
Post# 36215480

RE:RE:RE:RE:NCIB tapped out...

RE:RE:RE:RE:NCIB tapped out...Answered Q2 -- reviewed by outside counsel and accountants who found no effect on assets, contracts, cash flows.  No w-rotten apples left!

Better to take advantage of weak hands than to have weak hands -- weak-handed investing often leads to buying high on momentum and selling low when it breaks.  The market is there to facilitate trades, not to tell you what anything is worth.

Take a look at fundamentals and tell me what the price should be without looking at what weak hands will sell at.  Do you think a 10ish% discount to book is the right answer when its market comp is 2x book?

Goldman Sachs has been an active buyer, FWIW.  It is probable, but not certain, that they are not buying for someone's retirement fund, their prop book is buying to make 2024 profits.  Step one is quiet accumulation.  Step two is fast accumulation in a quiet market (Friday lunch hour?) to cheaply take out technicals ($13 the most obvious but they may target others).  Step three is quiet selling as technical traders and returning weak hands bid the price up.

How much downside is left here?  To CAD11 (bought deal price a year ago) maybe?  How much upside?  This year to $15, one year out at average PT $20ish?  As an investor -- not a day or swing trader -- I like that math.

Dunno what you are -- sad guy in mom's basement I expect -- but I do appreciate the opportunity to sharpen my investment thesis.
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities